TCMD — Tactile Systems Technology, Inc. stock price, charts and financials
QT79Tactile Systems Technology, Inc.Tactile Systems Technology, Inc. (NASDAQ: TCMD) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
29.35
-0.15-0.50%
TA
Loading chart...
Snapshot
| Index | - | P/E | 32.78 | EPS (ttm) | 0.90 | Insider Own | 8.72% | Shs Outstand | 22.56M | Perf Week | 4.72% |
| Market Cap | 665.41M | Forward P/E | 18.85 | EPS next Y | 1.57 | Insider Trans | -2.78% | Shs Float | 22.08M | Perf Month | -3.85% |
| Enterprise Value | 605.59M | PEG | 0.90 | EPS next Q | - | Inst Own | - | Short Float | 11.09% | Perf Quarter | 13.42% |
| Income | 20.30M | P/S | 1.94 | EPS this Y | 28.98% | Inst Trans | - | Short Ratio | 8.18 | Perf Half Y | 8.42% |
| Sales | 343.52M | P/B | 3.05 | EPS next Y | 37.89% | ROA | 7.46% | Short Interest | 2.45M | Perf YTD | 1.72% |
| Book/sh | - | P/C | 15.83 | EPS next 5Y | 40.17% | ROE | 9.70% | 52W High | 37.58 -21.90% | Perf Year | 145.42% |
| Cash/sh | - | P/FCF | 17.02 | EPS past 3/5Y | - | ROIC | 7.93% | 52W Low | 11.81 148.53% | Perf 3Y | 34.21% |
| Dividend Est. | - | EV/EBITDA | 14.59 | Sales past 3/5Y | 10.14% 12.03% | Gross Margin | 75.68% | Volatility | 3.69% 3.94% | Perf 5Y | -39.77% |
| Dividend TTM | - | EV/Sales | 1.76 | EPS Y/Y TTM | 25.71% | Oper. Margin | 9.40% | ATR (14) | 1.13 | Perf 10Y | 166.25% |
| Dividend Ex-Date | - | Quick Ratio | 3.78 | Sales Y/Y TTM | 17.41% | Profit Margin | 5.91% | RSI (14) | 55.93 | Recom | 2.45 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.24 | EPS Q/Q | 38.46% | SMA20 | 3.45% | Beta | 0.81 | Target Price | 40.67 |
| Payout | 0.00% | Debt/Eq | 0.07 | Sales Q/Q | 22.95% | SMA50 | 5.84% | Rel Volume | 0.64 | Prev Close | 29.50 |
| Employees | 1,086 | LT Debt/Eq | 0.06 | Earnings | Aug 10 | SMA200 | 11.29% | Avg Volume | 253.03K | Price | 29.35 |
| IPO Date | Jul 28, 2016 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 33.33% 6.65% | Net Debt/EBITDA | -1.44 | Volume | 161,262 | Change | -0.50% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| May-07-26 | Upgrade | B. Riley Securities | Neutral → Buy | |
| May-05-26 | Reiterated | BTIG | Buy | $38 → $40 |
| Feb-18-26 | Reiterated | Lake Street | Buy | $32 → $40 |
| Feb-18-26 | Reiterated | BTIG | Buy | $28 → $38 |
| Feb-18-26 | Reiterated | Piper Sandler | Overweight | $35 → $42 |
| Jan-05-26 | Reiterated | Raymond James | $35 | |
| Jan-05-26 | Upgrade | Piper Sandler | Neutral → Overweight | $20 → $35 |
| Nov-04-25 | Reiterated | Piper Sandler | Neutral | $14 → $20 |
| Nov-04-25 | Reiterated | Lake Street | Buy | $24 → $32 |
| Nov-04-25 | Upgrade | BTIG | Neutral → Buy | $16 → $28 |
Latest News
Aug-06-26
Jul-21-26
Jul-21-2604:05PM
Jul-14-26
Jul-13-26
Jul-13-2608:00AM
Jun-29-26
Jun-29-2606:56AM
Jun-26-26
Company
Tactile Systems Technology, Inc. is a medical technology firm that develops and supplies specialized devices to treat chronic health conditions across the United States. Its product portfolio features the Flexitouch Plus system, a pneumatic compression device designed for managing lymphedema. The company also offers the Entre system, a portable pneumatic compression solution for at-home treatment of various venous disorders, including lymphedema, chronic venous insufficiency, and venous leg ulcers. Additionally, Tactile Systems provides the AffloVest, a portable high-frequency chest wall oscillation device used to address retained pulmonary secretions associated with conditions such as bronchiectasis, cystic fibrosis, and certain neuromuscular disorders. Established in 1995, the company maintains its headquarters in Minneapolis, Minnesota.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 344 | 330 | 293 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 84 | 82 | 76 | — | — | — | — | — | — | |
| Gross Profit | 261 | 248 | 217 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 218 | 210 | 183 | — | — | — | — | — | — | |
| Research and Development | 10 | 8 | 9 | — | — | — | — | — | — | |
| Other Operating Expense | 0 | 0 | 3 | — | — | — | — | — | — | |
| Operating Income | 32 | 29 | 22 | — | — | — | — | — | — | |
| Interest Expense | 0 | 1 | 2 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 3 | 3 | 3 | — | — | — | — | — | — | |
| Net Income Before Taxes | 34 | 31 | 23 | — | — | — | — | — | — | |
| Income Taxes | 14 | 12 | 7 | — | — | — | — | — | — | |
| Consolidated Net Income | 20 | 19 | 17 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 20 | 19 | 17 | — | — | — | — | — | — | |
| Net Income | 20 | 19 | 17 | — | — | — | — | — | — | |
| EPS (Recurring) | 0.90 | 0.83 | 0.71 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.90 | 0.83 | 0.71 | — | — | — | — | — | — | |
| EPS (Diluted) | 0.88 | 0.82 | 0.70 | — | — | — | — | — | — | |
| EBITDA | 42 | 39 | 32 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 33.36 | 35.37 | 24.47 | — | — | — | — | — | — | |
| Price To Sales Ratio | 1.96 | 2.02 | 1.40 | — | — | — | — | — | — | |
| Gross Margin | 75.87 | 75.15 | 74.06 | — | — | — | — | — | — | |
| Operating Margin | 9.30 | 8.79 | 7.51 | — | — | — | — | — | — | |
| Net Margin | 5.81 | 5.76 | 5.80 | — | — | — | — | — | — | |
| Shares Outstanding | 23 | 23 | 24 | — | — | — | — | — | — | |
| Market Capitalization | 675 | 667 | 411 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Birkemeyer Elaine M. | CHIEF FINANCIAL OFFICER | May 11 '26 | Sale | 24.49 | 4,631 | 113,404 | 130,188 | May 13 |
| Dodd Sheri Louise | Chief Executive Officer | Feb 24 '26 | Sale | 28.94 | 10,993 | 318,144 | 243,885 | Feb 26 |
| Birkemeyer Elaine M. | CHIEF FINANCIAL OFFICER | Feb 24 '26 | Sale | 28.94 | 7,701 | 222,880 | 134,819 | Feb 26 |
| Burns Kristie | Sr. VP Mktg & Clinical Affairs | Feb 24 '26 | Sale | 28.94 | 6,246 | 180,764 | 82,581 | Feb 26 |
| Dodd Sheri Louise | Chief Executive Officer | Feb 23 '26 | Sale | 28.30 | 15,240 | 431,245 | 254,878 | Feb 24 |
| Birkemeyer Elaine M. | CHIEF FINANCIAL OFFICER | Feb 23 '26 | Sale | 28.30 | 5,518 | 156,144 | 142,520 | Feb 24 |
| Burns Kristie | Sr. VP Mktg & Clinical Affairs | Feb 23 '26 | Sale | 28.30 | 4,439 | 125,612 | 88,827 | Feb 24 |
| Burns Kristie | Sr. VP Mktg & Clinical Affairs | Jan 02 '26 | Sale | 28.85 | 5,139 | 148,260 | 72,401 | Jan 06 |
| Dodd Sheri Louise | Chief Executive Officer | Aug 08 '25 | Sale | 12.36 | 7,762 | 95,907 | 173,479 | Aug 12 |
| Birkemeyer Elaine M. | Chief Financial Officer | May 12 '25 | Sale | 9.94 | 2,921 | 29,037 | 99,111 | May 14 |
| Dodd Sheri Louise | Chief Executive Officer | May 08 '25 | Sale | 9.83 | 3,149 | 30,955 | 181,241 | May 12 |
| BURKE WILLIAM W | Director | May 08 '25 | Sale | 9.67 | 3,300 | 31,911 | 48,520 | May 09 |
| Birkemeyer Elaine M. | Chief Financial Officer | Feb 25 '25 | Sale | 14.51 | 2,066 | 29,980 | 102,032 | Feb 27 |
| Burns Kristie | Sr. VP Mktg & Clinical Affairs | Feb 25 '25 | Sale | 14.40 | 6,468 | 93,160 | 77,540 | Feb 27 |
| REUVERS DANIEL L. | Director | Feb 25 '25 | Sale | 14.18 | 28,338 | 401,850 | 214,604 | Feb 27 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.